MA45552A - Compositions destinées au traitement de l'amylose - Google Patents

Compositions destinées au traitement de l'amylose

Info

Publication number
MA45552A
MA45552A MA045552A MA45552A MA45552A MA 45552 A MA45552 A MA 45552A MA 045552 A MA045552 A MA 045552A MA 45552 A MA45552 A MA 45552A MA 45552 A MA45552 A MA 45552A
Authority
MA
Morocco
Prior art keywords
amylosis
compositions
treatment
Prior art date
Application number
MA045552A
Other languages
English (en)
Inventor
Spencer D Guthrie
Gene G Kinney
Martin Koller
Original Assignee
Prothena Biosciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prothena Biosciences Ltd filed Critical Prothena Biosciences Ltd
Publication of MA45552A publication Critical patent/MA45552A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA045552A 2016-06-30 2017-06-30 Compositions destinées au traitement de l'amylose MA45552A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662357151P 2016-06-30 2016-06-30

Publications (1)

Publication Number Publication Date
MA45552A true MA45552A (fr) 2019-05-08

Family

ID=59351103

Family Applications (1)

Application Number Title Priority Date Filing Date
MA045552A MA45552A (fr) 2016-06-30 2017-06-30 Compositions destinées au traitement de l'amylose

Country Status (16)

Country Link
US (2) US20190169280A1 (fr)
EP (1) EP3478713B1 (fr)
JP (3) JP2019519584A (fr)
CY (1) CY1125536T1 (fr)
DK (1) DK3478713T3 (fr)
ES (1) ES2914781T3 (fr)
HR (1) HRP20220979T8 (fr)
HU (1) HUE059400T2 (fr)
LT (1) LT3478713T (fr)
MA (1) MA45552A (fr)
PL (1) PL3478713T3 (fr)
PT (1) PT3478713T (fr)
RS (1) RS63446B1 (fr)
SI (1) SI3478713T1 (fr)
SM (1) SMT202200261T1 (fr)
WO (1) WO2018005967A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA202092264A1 (ru) * 2018-03-23 2020-12-03 Протена Байосайенсиз Лимитед Лечение и профилактика амилоидоза
CN113924099A (zh) * 2019-02-12 2022-01-11 普罗塞纳生物科学有限公司 针对免疫球蛋白轻链的单克隆抗体与抗体产生细胞和其他免疫细胞上的cd38细胞膜分子的组合治疗al淀粉样变性
JP7619953B2 (ja) * 2019-03-05 2025-01-22 プロシーナ バイオサイエンシーズ リミテッド Ａｌアミロイドーシスを処置する方法
WO2021041884A1 (fr) * 2019-08-30 2021-03-04 Alnylam Pharmaceuticals, Inc. Chaîne légère neurofilamentaire (nfl) en tant que biomarqueur pour la polyneuropathie liée une amylose à transthyrétine
TW202216768A (zh) * 2020-06-22 2022-05-01 美商恩格姆生物製藥公司 Ｌａｉｒ－１結合劑及其使用方法
TW202332465A (zh) * 2021-01-29 2023-08-16 愛爾蘭商普羅希那生物科學有限公司 治療al類澱粉變性症之方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1355919E (pt) 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
ES2544679T3 (es) 2007-12-28 2015-09-02 Prothena Biosciences Limited Tratamiento y profilaxis de la amiloidosis
PE20191242A1 (es) 2011-10-25 2019-09-16 Prothena Biosciences Ltd Formulaciones de anticuerpo y metodos

Also Published As

Publication number Publication date
PL3478713T3 (pl) 2022-10-10
ES2914781T3 (es) 2022-06-16
LT3478713T (lt) 2022-06-10
SI3478713T1 (sl) 2022-06-30
US20190169280A1 (en) 2019-06-06
HRP20220979T1 (hr) 2022-11-11
CY1125536T1 (el) 2025-05-09
RS63446B1 (sr) 2022-08-31
PT3478713T (pt) 2022-05-27
SMT202200261T1 (it) 2022-07-21
JP2024127990A (ja) 2024-09-20
HUE059400T2 (hu) 2022-11-28
US20210079078A1 (en) 2021-03-18
EP3478713B1 (fr) 2022-05-11
JP2022121658A (ja) 2022-08-19
JP2019519584A (ja) 2019-07-11
HRP20220979T8 (hr) 2023-02-03
EP3478713A1 (fr) 2019-05-08
WO2018005967A1 (fr) 2018-01-04
DK3478713T3 (da) 2022-06-20

Similar Documents

Publication Publication Date Title
FR25C1001I2 (fr) Compositions d'anticorps pour le traitement de tumeurs
MA45192A (fr) Traitement d'association
MA47719A (fr) Esketamine pour le traitement de la dépression
EP3448875A4 (fr) Compositions pour le traitement de maladies
EP3448987A4 (fr) Compositions pour le traitement de maladies
EP3370721A4 (fr) Traitement de l'ostéoarthrite
MA44083A (fr) Composés de biarylmonobactame pour le traitement d'infections bactériennes
EP3380200A4 (fr) Compositions pour le traitement des cheveux
MA46524A (fr) Composés de biphényl-sulfonamide destinés au traitement de néphropathies
EP3541408A4 (fr) Compositions et méthodes pour le traitement de l'angiogenèse aberrante
EP3443094A4 (fr) Procédés de réduction de l'expression de c9orf72
FR3056393B1 (fr) Orthese d'extension de machoires
MA45552A (fr) Compositions destinées au traitement de l'amylose
EP3541379A4 (fr) Compositions pour le traitement de l'hypertension
EP3380063A4 (fr) Compositions pour le traitement des cheveux
EP3344256A4 (fr) Compositions destinées au traitement des articulations
EP3538219A4 (fr) Compositions topiques destinées au traitement de l'acné
PL3573620T3 (pl) Kompozycje do leczenia nadciśnienia
EP3716966A4 (fr) Compositions d'alpha-cétoacides pour le traitement de l'hypoalbuminémie
EP3347032A4 (fr) Traitement de l'ascite
EP3655036C0 (fr) Compositions pour le traitement de troubles liès au stress
EP3270968C0 (fr) Nouvelles compositions antivirales pour le traitement de la grippe
EP3344650A4 (fr) Aav-epo pour le traitement d'animaux de compagnie
EP3373922A4 (fr) Compositions et méthodes pour le traitement de l'homocystinurie
EP3632430A4 (fr) Agent de prévention ou de traitement de l'ataxie spinocérébelleuse